Acurx Pharmaceuticals (ACXP) vs Aprea Therapeutics (APRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aprea Therapeutics is the larger company by market cap ($7.0 million vs $6.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | APRE |
|---|---|---|
| Share price | $1.25 | $0.5582 |
| Market cap | $6.95M | $7.03M |
| 1-day change | -3.85% | -7.74% |
| EPS (TTM) | $-2.67 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $1.69 |
| 52-week low | $1.23 | $0.548 |
| Distance from 52-week high | -84.34% | -66.97% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1260.00% | +568.22% |
| Average volume | 125.08K | 280.14K |
| Shares outstanding | 5.56M | 12.59M |
| Employees | 4 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
ACXP vs APRE FAQ
Which is bigger, Acurx Pharmaceuticals or Aprea Therapeutics?
Aprea Therapeutics (APRE) is larger, with a market capitalization of $7.03M compared with $6.95M for Acurx Pharmaceuticals (ACXP).
Are Acurx Pharmaceuticals and Aprea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.